Join the 'Otovel' group to help and get support from people like you.
Posted 26 Jul 2016 by Drugs.com
TUESDAY, July 26, 2016 – The U.S. Food and Drug Administration announced Tuesday that it's strengthening label warnings on a class of antibiotics called fluoroquinolones because the drugs can lead to disabling side effects, including long-term nerve damage and ruptured tendons. The agency also cautioned that these bacteria-fighting drugs – including levofloxacin (Levaquin) and ciprofloxacin (Cipro) – shouldn't be prescribed for sinusitis, chronic bronchitis or simple urinary tract infections unless no other treatments options exist. "Fluoroquinolones have risks and benefits that should be considered very carefully," Dr. Edward Cox said in an FDA news release. He's director of the Office of Antimicrobial Products at the FDA's Center for Drug Evaluation and Research. "It's important that both health care providers and patients are aware of both the risks and benefits of ... Read more
Related support groups: Infections, Urinary Tract Infection, Peripheral Neuropathy, Sinusitis, Bronchitis, Bladder Infection, Cipro, Ciprofloxacin, Levaquin, Levofloxacin, Kidney Infections, Avelox, Myasthenia Gravis, Ofloxacin, Vigamox, Ciprodex, Moxifloxacin, Sinus Symptoms, Gatifloxacin, Gemifloxacin